Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + paclitaxel + varlitinib
- Development stage
- Phase 2
- Lead developer
- ASLAN Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination regimen consisting of three drugs: - **Carboplatin**: A platinum-based chemotherapy agent that causes DNA crosslinking and apoptosis in rapidly dividing cells. - **Paclitaxel**: A microtubule-stabilizing agent that inhibits cell division by preventing microtubule depolymerization. - **Varlitinib**: An oral, highly potent small-molecule pan-HER inhibitor targeting HER1 (EGFR), HER2, and HER4. Varlitinib blocks the kinase activity of these receptors, inhibiting downstream signaling pathways involved in tumor growth and survival. The triplet combination has been investigated in phase Ib studies for advanced or metastatic solid tumors, including HER2-positive breast cancer. However, the full triplet was found to be intolerable due to dose-limiting toxicities such as neutropenia and electrolyte disturbances; development focused instead on varlitinib plus paclitaxel[1][2]. The regimen was explored primarily as a potential neoadjuvant therapy for HER2+ breast cancer.
- Other names
- paclitaxel + carboplatin + ASLAN001
02
Targets
DNAEGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on carboplatin + paclitaxel + varlitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + paclitaxel + varlitinib.